All Data
Lead Product(s): Succinylcholine Chloride
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 12, 2020
Details:
Dr. Reddy's Laboratories has launched Succinylcholine Chloride Injection USP, 200 mg/10 mL (20 mg/mL), Multiple-Dose Vials a therapeutic equivalent generic version of Quelicin® (Succinylcholine Chloride) Injection, 20 mg/mL, approved by the USFDA.
Our shared vision is to have a World, free of Pain.
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Tetridar
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Teva Pharmaceutical Industries
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement September 18, 2020
Details:
Grünenthal and Teva have reached an exclusive agreement for the marketing, distribution, and promotion of teriparatide (Tetridar) in the Spanish market.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Chugai Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Termination January 22, 2021
Details:
Chugai Pharmaceutical and Taisho Pharmaceutical announced termination of the agreement between both companies regarding co-marketing of Edirol® Capsules 0.5 µg and 0.75 µg, a treatment for osteoporosis for which Chugai has a marketing authorization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Teriparatide
Therapeutic Area: Musculoskeletal Product Name: Livogiva
Highest Development Status: Approved Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 18, 2021
Details:
Livogiva is a new presentation of teriparatide, the only bone anabolic treatment for osteoporosis, which has been developed as a pre-filled pen making it easy to use for patients at high risk of fractures.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Celecoxib
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 13, 2021
Details:
Unichem Laboratories announced that it has received ANDA approval for its Celecoxib Capsules, 50 mg, 100 mg, 200 mg, and 400 mg from the USFDA to market a generic version of CELEBREX® (Celecoxib) Capsules of G.D. Searle LLC, Division of Pfizer Inc.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Onasemnogene abeparvovec-xioi
Therapeutic Area: Musculoskeletal Product Name: Zolgensma
Highest Development Status: Approved Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Healthcare Royalty Management
Deal Size: Undisclosed Upfront Cash: $200.0 million
Deal Type: Agreement December 22, 2020
Details:
REGENXBIO will receive $200 million from HCR as an upfront payment in exchange for REGENXBIO's royalty rights from the net sales of Zolgensma. Agreement provides REGENXBIO with significant additional non-dilutive funding to advance RGX-314 and RGX-121.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Eldecalcitol
Therapeutic Area: Musculoskeletal Product Name: Edirol
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 18, 2020
Details:
Chugai has obtained regulatory approval for eldecalcitol (product name: Edirol®), an active vitamin D3 derivative created by Chugai from the China National Medical Products Administration (NMPA).
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Succinylcholine Chloride
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 29, 2020
Details:
Nexus Pharmaceuticals has received U.S. Food and Drug Administration (FDA) approval for Succinylcholine Chloride Injection, USP in 200mg/10mL Multiple-Dose Vials. It is an AP-rated generic to QUELICIN.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dantrolene Sodium
Therapeutic Area: Musculoskeletal Product Name: Ryanodex
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: JPMorgan Chase Bank
Deal Size: $160.0 million Upfront Cash: Undisclosed
Deal Type: Investment September 24, 2020
Details:
The accelerated share repurchase program will support Eagle's multiple anticipated and ongoing drug development activities which include RYANODEX franchise, anticipated near-term launch of vasopressin, and three potential oncology launches PEMFEXY, fulvestrant and SM-88.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Tolperisone
Therapeutic Area: Musculoskeletal Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2020
Details:
The presentation will highlight results from a double-blind, randomized, placebo-controlled, multicenter phase 3 study evaluating Tolperisone 100 and 200 mg Three Times Daily (TID) for acute muscle spasm of the back.
Drugs in Development
Market Place
Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace
